Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 24;11:3726. doi: 10.1038/s41467-020-17127-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a–c Parental BRCA^MUT (PEO1, JHOS4) (a), acquired PARPi and platinum-resistant (PEO-PR, JHOS4-PR, PEO1-CR, and PEO1-CR2) (b), and platinum-resistant CCNE1^AMP (OVCAR3, COV318, and FUOV1) (c), cells were treated with PARPi (1 μM for PEO1, JHOS4, PEO-PR, JHOS4-PR, PEO1-CR, PEO1-CR2, and OVCAR3; 2 μM for COV318 and FUOV1) and ATRi (1 μM for all cell lines) monotherapy and their combination, and then evaluated for cell-cycle by flow cytometry; G2-M phase changes (left panel) and cell-cycle phase distribution at 24 h (right panel) are shown. In parental BRCA1/2^MUT PARPi-sensitive cells, there was a significant increase in G2-M with PARPi treatment that was overcome with the addition of ATRi treatment (PEO1 and JHOS4, P < 0.0001 Control vs PARPi and PARPi vs Both). In platinum-resistant, CCNE1^AMP (OVCAR3, COV318, and FUOV1) cells, there was a significant increase in G2-M with PARPi treatment that was overcome with the addition of ATRi (OVCAR3 and COV318, P < 0.0001 Control vs PARPi and PARPi vs Both; FUOV1, P = 0.0005 Control vs PARPi, P = 0.004 PARPi vs Both). In the acquired PARPi and platinum-resistant cells, effects of PARPi treatment on G2/M were insignificant (P > 0.05) and with the addition of ATRi, the effects on G2-M were less striking as in parental and CCNE1^AMP lines (P > 0.05 except P < 0.0001 for JHOS4-PR and P = 0.01 for PEO1-CR2). The data are presented as mean ± SD (n = 3 biologically independent samples). Individual samples are presented as data points overlaying bar grafts. The data were analyzed with one-way ANOVA followed by Tukey’s test. ***P < 0.001, **P < 0.01, *P < 0.05, NS = not significant. Source data are provided as a source data file.